TABLE 3.

Susceptibilities of gram-negative bacteria isolated from bloodstream specimens of hospitalized patients in four European countries, Canada, and the United States to antimicrobials^a

Organism	Antimicrobial agent	France		Germany		Italy		Spain		Canada		United States
		No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible
E. coli	Cefotaxime	5,265	99.5	2,620	99.6	1,113	97.8	2,175	98.5	1,170	96.8	4,905	98.1
	Ceftazidime	4,651	98.7	1,501	99.3	1,698	97.6	2,041	98.4	2,013	98.5	6,892	96.9
	Ceftriaxone	813	99.3	186	100	1,363	98.1	492	99.4	1,585	97.9	6,460	98.2
	Ciprofloxacin	4,659	93.9	2,072	89.0	1,697	81.3	2,253	81.0	2,280	93.5	7,547	90.9
	Gentamicin	5,265	96.4	2,503	96.8	1,689	91.7	2,138	91.5	2,419	94.5	9,022	94.1
	TMP-SMX	5,090	77.9	2,524	73.5	1,490	71.5	2,229	66.4	2,535	79.8	8,854	75.7
Klebsiella spp.	Cefotaxime	846	95.7	710	95.1	313	93.0	551	90.9	618	98.1	3,143	92.2
	Ceftazidime	754	96.3	400	92.5	458	87.3	528	91.1	949	98.4	4,394	89.4
	Ceftriaxone	174	94.3	58	100	364	91.2	83	95.2	709	97.7	4,114	91.9
	Ciprofloxacin	793	94.3	581	90.9	458	94.5	587	94.0	1,083	96.1	4,663	92.5
	Gentamicin	843	98.2	665	96.8	463	92.0	566	89.9	1,177	97.2	5,472	91.8
	TMP-SMX	798	90.7	675	86.8	420	85.5	586	84.6	1,215	92.0	5,333	87.2
P. mirabilis	Cefotaxime	337	98.8	210	99.5	111	56.8	196	100	52	100	598	99.5
	Ceftazidime	297	98.3	131	99.2	171	78.4	182	100	112	100	807	98.1
	Ceftriaxone	NAb	NA	NA	NA	158	69.6	NA	NA	100	100	772	99.7
	Ciprofloxacin	298	85.2	174	87.4	174	63.8	206	86.9	134	95.5	849	80.0
	Gentamicin	336	93.5	198	90.9	175	52.6	197	90.4	149	92.0	1,044	87.0
	TMP-SMX	325	83.7	199	66.8	166	54.2	202	62.4	153	89.5	1,033	77.5
S. marcescens	Cefotaxime	166	76.5	162	84.0	110	89.1	90	92.2	92	88.0	759	86.0
	Ceftazidime	153	90.9	114	92.1	158	90.5	76	93.4	185	91.9	1,052	90.1
	Ceftriaxone	NA	NA	NA	NA	119	81.5	NA	NA	157	94.9	992	91.8
	Ciprofloxacin	156	69.9	155	72.9	158	93.0	98	92.9	215	93.5	1,081	92.1
	Gentamicin	167	88.6	114	88.6	159	96.9	95	100	223	91.5	1,256	94.8
	TMP-SMX	160	80.0	157	90.5	139	90.7	99	99.0	222	95.5	1,210	96.6
Citrobacter spp.	Cefotaxime	132	81.1	107	85.1	57	77.2	56	83.9	67	80.6	403	79.9
	Ceftazidime	123	79.7	66	72.7	78	68.0	51	72.6	93	82.8	554	75.6
	Ceftriaxone	NA	NA	NA	NA	60	75.0	NA	NA	64	85.9	516	80.0
	Ciprofloxacin	123	90.2	78	93.6	77	90.9	68	89.7	116	92.2	592	89.4
	Gentamicin	132	92.4	105	95.2	78	94.9	67	100	116	88.8	683	90.8
	TMP-SMX	124	89.5	110	94.6	71	90.1	68	91.2	121	87.6	663	85.7
Enterobacter spp.	Cefotaxime	658	72.5	384	78.7	290	56.9	257	70.0	322	73.0	470	72.3
	Ceftazidime	616	69.3	237	69.6	419	52.3	251	66.5	519	79.8	653	66.5
	Ceftriaxone	158	62.7	NA	NA	317	53.3	NA	NA	432	78.9	616	69.6
	Ciprofloxacin	601	79.7	312	94.9	423	72.3	323	94.4	615	96.1	669	91.8
	Gentamicin	652	95.3	354	96.9	421	80.3	305	99.7	612	96.6	795	93.7
	TMP-SMX	621	84.5	379	97.1	389	78.7	321	92.2	628	95.1	771	92.7
P. aeruginosa	Amikacin	709	81.0	176	94.9	644	84.9	446	97.3	282	90.4	2,480	92.4
	Cefepime	635	66.8	206	85.0	436	60.1	401	79.6	NA	NA	2,429	80.6
	Cefotaxime	NA	NA	139	13.0	442	9.1	325	7.4	177	21.5	1,416	9.3
	Ceftazidime	705	80.0	293	84.6	783	62.7	492	82.1	532	80.8	3,167	80.8
	Ceftriaxone	NA	NA	NA	NA	503	9.0	NA	NA	311	10.0	1,823	12.8
	Ciprofloxacin	703	67.0	262	75.2	773	66.1	487	82.8	538	78.1	3,068	73.1
	Gentamicin	700	51.6	254	79.9	775	59.5	473	75.3	505	78.6	3,448	78.7
	Imipenem	711	81.7	265	84.2	761	70.6	427	82.9	390	84.4	2,988	83.6
	Piperacillin-tazobactam	670	78.1	275	92.4	446	81.2	407	86.7	411	88.8	2,495	90.1

^aData are cumulative for 2000 to 2001.

^bNA, not available, <50 results were available.